MedTrace Logo

Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

NCT04971590 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193

Last updated 2026-01-22

Study results available
· View outcomes & findings →

Summary

This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).

Conditions

Interventions

OTHER

Participant completed survey

Participants will be required to complete the participant survey.

OTHER

Medical chart review

Data will be collected from medical charts of participants.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • Kuwait
  • Oman
  • Qatar
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04971590 on ClinicalTrials.gov